WHO Model Prescribing Information: Drugs Used in HIV-Related Infections
(1999; 58 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Abrir esta carpeta y ver su contenidoOpportunistic infections
Abrir esta carpeta y ver su contenidoRespiratory disease
Abrir esta carpeta y ver su contenidoNeurological disorders
Abrir esta carpeta y ver su contenidoOpthalmological complications
Abrir esta carpeta y ver su contenidoFebrile illness
Abrir esta carpeta y ver su contenidoGastrointestinal tract/diarrhoeal disease
Abrir esta carpeta y ver su contenidoMucocutaneous and cutaneous eruptions
Cerrar esta carpetaDrugs
Ver el documentoAciclovir
Ver el documentoAlbendazole
Ver el documentoAmphotericin B
Ver el documentoAzithromycin
Ver el documentoBenzylpenicillins
Ver el documentoCalcium folinate
Ver el documentoCeftriaxone
Ver el documentoCiprofloxacin
Ver el documentoClarithromycin
Ver el documentoClindamycin
Ver el documentoCodeine
Ver el documentoDapsone
Ver el documentoFluconazole
Ver el documentoFlucytosine
Ver el documentoFoscarnet
Ver el documentoGanciclovir
Ver el documentoItraconazole
Ver el documentoKetoconazole
Ver el documentoNystatin
Ver el documentoPentamidine
Ver el documentoPrimaquine
Ver el documentoPyrimethamine
Ver el documentoRifabutin
Ver el documentoSulfadiazine
Ver el documentoSulfadoxine/Pyrimethamine (Fansidar)
Ver el documentoSulfamethoxazole/Trimethoprim (Cotrimoxazole)
Ver el documentoTrimethoprim
Ver el documentoBack Cover
 

Albendazole

Group: anthelminthic/antiprotozoal
Tablet, 200 mg, 400 mg [EDL] chewable tablet

General information

Albendazole is a benzimidazole carbamate anthelminthic which is also active against various protozoa. Albendazole is poorly and variably absorbed from the GI tract but absorption is increased when administered with a fatty meal. It undergoes extensive first pass metabolism. The active principal metabolite has a plasma half-life of about 8.5 hours. It is excreted in the urine.

Clinical information

Uses

Treatment and suppression of microsporidial infections

Dosage and administration

Treatment and suppression of microsporidial infections: 400 mg twice a day for four weeks. If the patient relapses after therapy is stopped, it should be assumed that the microsporidia has not been completely cleared and suppressive therapy of 400 mg once a day will be required after the infection has been brought under control with the original treatment dose.

To increase absorption albendazole should be taken with a fatty meal.

Contraindications

Known hypersensitivity; pregnancy

Precautions

Monitor liver function tests, and full blood count during therapy.

Use in pregnancy

In animal studies albendazole has been found to be teratogenic and therefore should not be used.

Adverse effects

Elevations in liver function tests, and reversible reductions in total white cell counts and pancytopenia have been reported. Mild gastrointestinal disturbances, headaches, dizziness, alopecia (limited to thinning of the hair) have also been reported.

Drug interactions

Albendazole has been shown to induce liver enzymes of the cytochrome P450 system responsible for its own metabolism. Therefore, there is a theoretical risk of interaction with theophylline, anticonvulsants, oral contraceptives, and oral hypoglycaemic agents.

Overdosage

There is no experience of overdosage. Gastric lavage may be performed in the first two to three hours after ingestion. No specific antidote is known.

Storage

Tablets should be stored in tightly closed containers protected from light.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 24 abril 2012